Sign In
Buy ZVRA
$13.00
+0.350 (+2.77%)
At Close: Jun 23, 2026
Wall Street Analysts Predict an 86.55% Upside in Zevra Therapeutics (ZVRA): Here's What You Should Know
10:56am, Tuesday, 15'th Jul 2025
The average of price targets set by Wall Street analysts indicates a potential upside of 86.6% in Zevra Therapeutics (ZVRA). While the effectiveness of this highly sought-after metric is questionable,
Here's Why 'Trend' Investors Would Love Betting on Zevra Therapeutics (ZVRA)
09:50am, Tuesday, 15'th Jul 2025
Zevra Therapeutics (ZVRA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed thr
Zevra Therapeutics (ZVRA) Moves 5.1% Higher: Will This Strength Last?
09:21am, Thursday, 03'rd Jul 2025
Zevra Therapeutics (ZVRA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength d
Zevra Therapeutics initiated with bullish view at H.C. Wainwright, here's why
06:07am, Wednesday, 02'nd Jul 2025
09 Aug 09 Aug
Zevra Announces Final Results of 2025 Annual Meeting of Stockholders
04:35pm, Thursday, 29'th May 2025
Zevra Stockholders Re-Elect Wendy L. Dixon, Ph.D.
ISS, Glass Lewis, and Egan-Jones Unanimously Conclude Mangless Has Not Made a Compelling Case for Change Board and Management Urge Stockholders to Follow Proxy Advisors' Recommendation and Vote “FOR
Zevra Therapeutics, Inc. (ZVRA) Q1 2025 Earnings Call Transcript
10:45pm, Tuesday, 13'th May 2025
Zevra Therapeutics, Inc. (NASDAQ:ZVRA ) Q1 2025 Earnings Conference Call May 13, 2025 4:30 PM ET Company Participants Nichol Ochsner - Vice President Neil McFarlane - President and Chief Executive Off
Zevra Therapeutics (ZVRA) Reports Q1 Loss, Tops Revenue Estimates
06:20pm, Tuesday, 13'th May 2025
Zevra Therapeutics (ZVRA) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.40 per share a year ago.
Zevra Therapeutics Announces Details for Q1 2025 Financial Results Call
07:30am, Tuesday, 06'th May 2025
Company will host conference call at 4:30 p.m. ET on Tuesday, May 13, 2025 Company will host conference call at 4:30 p.m. ET on Tuesday, May 13, 2025
Zevra Announces Publication of MIPLYFFA® Mechanism of Action Manuscript in Molecular Genetics and Metabolism
07:30am, Thursday, 17'th Apr 2025
CELEBRATION, Fla., April 17, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living wit
Zevra Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million
07:30am, Monday, 07'th Apr 2025
CELEBRATION, Fla., April 07, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living wit
Zevra Therapeutics Files Preliminary Proxy
04:12pm, Monday, 31'st Mar 2025
Confirms Receipt of Two Director Nominees from Daniel J. Mangless Stockholders Are Not Required to Take Action at This Time CELEBRATION, Fla.
Zevra Therapeutics, Inc. (ZVRA) Q4 2024 Earnings Call Transcript
08:16pm, Tuesday, 11'th Mar 2025
Zevra Therapeutics, Inc. (NASDAQ:ZVRA ) Q4 2024 Earnings Conference Call March 11, 2025 4:30 PM ET Company Participants Nichol Ochsner - VP, IR and Corporate Communications Neil McFarlane - President
Zevra Therapeutics (ZVRA) Reports Q4 Loss, Tops Revenue Estimates
07:15pm, Tuesday, 11'th Mar 2025
Zevra Therapeutics (ZVRA) came out with a quarterly loss of $0.67 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to loss of $0.40 per share a year ago.
Zevra Reports Full Year 2024 and Fourth Quarter Financial Results
04:05pm, Tuesday, 11'th Mar 2025
FY 2024 net revenue of $23.6 million, driven by net revenue of $12.0 million during fourth quarter of 2024 Entered into asset purchase agreement for sale of PRV for $150 million Company to host confe
